Articles tagged with Tumor Growth
Researchers precisely measured protein levels in 1,400 tumor biopsies and found no correlation between HER3 protein levels and Herceptin treatment outcome. The study suggests that single biomarkers like HER3 are not predictive of benefit from Herceptin treatment.
Researchers at VTT Technical Research Centre of Finland discovered a single cell protein that inhibits both cell migration and growth in aggressive breast cancer cells. This finding suggests an interconnected regulation of uncontrollable growth and metastasis, potentially leading to new medicine development.
A study published in Journal of Interferon & Cytokine Research found that Tyk2 protein helps suppress breast tumor growth and metastasis. Mice with normal Tyk2 expression were less susceptible to breast cancer, suggesting boosting Tyk2 activity may be beneficial for treating the disease.
Researchers at Karolinska Institutet have found that treating common Cytomegalovirus (CMV) can reduce tumour growth and size. CMV is found in 70-75% of adults and plays a central role in brain tumours, breast cancer, colon cancer, and prostate cancer.
A study by Andrew Weng and colleagues identifies insulin growth factor-1 (IGF-1) as a key driver of cancer growth in T cell acute lymphoblastic leukemia. Blocking the IGF-1 receptor improves survival rates in mice, suggesting a potential new treatment strategy.
Scientists from the University of Miami and Germany have created a model to predict cancer tumor growth and progression, which could lead to highly individualized treatment strategies. The model analyzes images of tumor sections and predicts the most likely course of the disease.
Scientists at Dana-Farber Cancer Institute have identified a novel subtype of breast cancer that grows in response to androgen but not estrogen. The study reveals the signaling pathways involved in its growth and demonstrates that drugs capable of blocking these pathways can inhibit tumor growth.
A team of researchers has identified a new breast cancer tumor suppressor called Runx3, which regulates gene expression and targets the estrogen receptor alpha. The study found that Runx3 suppressed breast cancer cell growth and inhibited tumor formation in mice, offering potential benefits for early detection and treatment.
A new study has identified PI3Kinase gamma as a crucial protein in tumor growth and inflammation. Disrupting this enzyme prevents tumor cells from attracting immune cells, slowing down tumor development and metastasis.
A UNC laboratory study shows that Tacrolimus, a commonly used organ transplant rejection medication, inhibits breast cancer growth by over 70 percent in pre-clinical studies. The drug works by blocking new blood vessel growth to tumors, a therapeutic strategy to inhibit tumor growth.
A new study links obstructive sleep apnea (OSA) to increased tumor growth and aggressiveness in melanoma cancer cells in mice. Recurrent hypoxia, a hallmark of OSA, enhances tumor proliferation and necrosis.
A team of researchers from the University of Montreal has made a breakthrough in understanding the genetics of Meier-Gorlin Syndrome, a rare disorder characterized by short stature and abnormal development. The study identified three genes - ORC1L, ORC4L, and CDT1 - that play a critical role in DNA replication and cell growth.
A Tel Aviv University researcher has found that fibroblasts, a type of connective tissue cell, can be coerced into supporting inflammation and tumor growth. This discovery opens new avenues for drug research and may help manage inflammation to reduce cancer growth.
A new study shows that protein HRG activates specific immune cells to inhibit tumor growth and metastasis. HRG enhances chemotherapy effects and transforms inflammatory cells from promoting to inhibiting tumor growth.
Two compounds, called PITs (non-phosphoinositide PIP3 inhibitors), show promise in halting cancer growth by inducing cell death and limiting tumor growth in mice. These compounds interfere with cell signaling pathways, positioning them as a promising new approach to cancer treatment.
Individual cancer-causing mutations have a minor effect on tumor growth, increasing cell division rates and contributing to the accumulation of multiple mutations. The research suggests that significant tumor growth requires the slow accumulation of multiple mutations over years, explaining why many cancer-driving mutations are needed.
Researchers found that TAL1 promotes the expression of NKX3.1 in T cell acute lymphoblastic leukemia cells, driving their growth and proliferation. Eliminating NKX3.1 halted the growth of these cancerous cells in culture and after injection into mice.
Researchers found that human breast cancer cells overexpress the alpha 9 subunit of the nAchR, promoting tumor growth. Reducing α9-nAchRs inhibited tumor growth in laboratory experiments.
The Society for Industrial and Applied Mathematics (SIAM) awards the Julian Cole Lectureship every four years to recognize outstanding contributions to mathematical characterization and solution of challenging problems. This year, Professor John King received the award for his work on mathematical modeling of tumor growth.
Researchers found that chronic morphine use decreases levels of tumor angiogenesis, mediated by suppression of signaling induced by low oxygen concentrations. This effect suggests morphine may inhibit tumor growth and serve as an anti-angiogenic agent in cancer pain management.
A study found that mammographic tumor detectability decreases with age, primarily due to denser breast tissue masking tumors. The study suggests that lowered mammographic tumor detectability accounts for 79% of the poorer sensitivity in mammography screening among younger women.
Researchers developed a non-invasive MRI method to visualize and quantify tumor angiogenesis, a crucial process for cancer growth. The new technique uses nanotechnology and MRI to detect early stages of blood vessel formation, enabling more accurate diagnosis and treatment adjustments.
A team of researchers has discovered a protein called Ronin that recruits a co-regulator to bind to a specific DNA sequence, enabling the growth of embryonic stem cells. This finding may also contribute to understanding cancer growth and development.
Researchers at Sanford-Burnham Medical Research Institute have discovered a new application for the painkiller Sulindac as a potential anti-cancer treatment. By binding to the truncated form of nuclear receptor RXRα, Sulindac shuts down cancer cell growth and initiates cell death.
A DNA-vaccine targeting DLL4 inhibits the formation of new blood vessels in tumours, leading to reduced tumour growth. The vaccine was shown to be effective in mice with breast cancer, causing a tightly packed network of non-functional blood vessels and poor blood supply.
Scientists identified 'growth genes' that stimulate rapid growth in young animals, which are then progressively turned off as organs mature. This process, controlled by organ development, limits excessive growth and explains why organs maintain proportional size.
Scientists discovered that beta-interferon inhibits tumor growth by blocking its connection to the blood circulatory system and reducing the production of growth factors. This effect was seen in mice where tumors grew slower and formed fewer metastases, highlighting a new potential target for cancer therapy.
A preclinical model of human prostate cancer mimics primary tumors' genetic behavior, offering a platform for biomarker and drug discovery. High expression levels of delta-like ligand 4 in breast cancer predict poor prognosis.
A study by UC Davis researchers found that consuming walnuts can significantly slow prostate cancer growth in mice. The walnut diet resulted in smaller tumors and reduced levels of the protein IGF-1, which is associated with prostate cancer.
Recent studies suggest that triggering TLR7 and TLR8 can actually increase tumor cell survival, while a new soluble factor IFN-beta represses tumor growth by limiting blood vessel formation. Additionally, microRNA-31 has been identified as an oncogenic factor promoting lung cancer through the repression of specific tumor suppressor genes.
Researchers identified IFN-beta as a natural inhibitor of tumor blood vessel growth, limiting tumor growth and immune cell gene expression. This discovery provides insight into why IFN therapy benefits early cancer development.
Researchers discovered that gliomas can evade EGFR inhibitors by expressing alternative genes like KLHDC8, which halts tumor growth. This finding provides potential new targets and treatment strategies for brain tumors.
Researchers found that targeting fibroblast activation protein (FAP) in tumor microenvironment significantly reduced tumor growth in mice. FAP promotes tumor growth by disrupting signaling pathways and biological processes required for tumor growth.
A Mayo Clinic study found that routine annual evaluation of prostate growth is not a reliable predictor for prostate cancer development. However, if PSA levels are rising quickly, a prostate biopsy is recommended to determine if prostate cancer exists.
Researchers have discovered an alternative spliced form of tissue factor that contributes to cancer growth and angiogenesis. The protein is found in various tissues but plays a key role in promoting the development of new vessels to fuel tumor growth.
Researchers at Ohio State University found that diesel exhaust exposure induces the growth of new blood vessels in mice, suggesting a link between diesel fume exposure and cancer. The study's results show that even normal tissue can develop tumors after short-term exposure to diesel exhaust.
Research by Dr. Susanne Talcott found that extracts from Texas red wines decreased cancer cell growth in a comparable magnitude as other wines previously studied. The study suggests that moderate consumption of Texas wine may offer similar health benefits to those from other regions.
A DNA vector-based approach silences STAT3, inhibiting HCC cell growth and inducing apoptosis. This study demonstrates RNAi's therapeutic potential in treating HCC by targeting the STAT3 gene.
A single gene, EBNA1, plays a crucial role in the activation of EBV genes responsible for indiscriminate tumor cell growth. The LSUHSC research team discovered that oxidative stress regulates EBNA1's ability to activate these genes, leading to potential therapeutic approaches using existing treatments like Vitamin K.
A recent study found that carbohydrate restriction without weight loss can slow prostate tumor growth by lowering serum insulin levels. The researchers believe that this mechanism is key to fighting prostate cancer growth and potentially improving patient outcomes.
Vanderbilt University researchers have identified a gene signature linked to reduced relapse-free survival in breast cancer patients, especially those with estrogen receptor-positive tumors. The discovery suggests that assessing TGF-β signaling may aid in determining breast cancer prognosis and guiding treatment.
A team of scientists has discovered a compound that can block the growth of brain tumors by reversing the effects of an altered enzyme. The mutation in the IDH1 gene impairs the body's ability to control a protein that promotes tumor growth, but adding a modified form of alpha-KG can restore this balance.
Researchers at Wake Forest University School of Medicine discovered a protein called ferritin binds to HKa, promoting blood vessel formation that assists in tumor growth. The study suggests preventing the binding could block tumor growth, with implications for wound care.
Researchers found that overexpressing SOX9 restores retinoic acid sensitivity in melanomas and stops tumor growth. A combined therapeutic strategy may provide new hope for treating RA-resistant cancers like melanoma.
A study found that docosahexaenoic acid (DHA) can directly suppress arachidonic acid-induced proliferation of colon carcinoma cells, while also reducing viability. DHA supplementation may be a powerful tool to counteract AA- and PGE2-promoted colon cancer cell growth.
A new report published in Disease Models & Mechanisms reveals that tumors trigger the same immune response as wounds, with hemocytes replicating and adhering to tumor surfaces to limit growth. The study identifies key pathways in the fly's immune response to tumor growth and tissue disruption, shared with humans.
Researchers at Medical College of Wisconsin report promising results using drugs to inhibit angiogenesis in rat models of glioblastoma, a deadly brain tumor. Tumor size was reduced by 50-70% and survival time increased by 5-7 days
Researchers at Duke University have synthesized largazole, a marine algae extract with potential as an anti-cancer agent. The team's efficient synthetic route enables the production of gram-sized quantities, paving the way for further study and potential treatment of various cancers.
The study introduces HB-19, an experimental synthetic molecule that inhibits both tumor cell growth and angiogenesis. In mice models, HB-19 treatment suppresses tumor development and eliminates measurable tumors without toxicity.
Researchers at the University of Illinois have identified a new family of agents that inhibit the growth of estrogen-dependent breast cancer cells. These compounds specifically target the binding of estrogen-receptor complex to regulatory regions of genes, effectively retarding protein production and cell proliferation.
Researchers found that primary tumors can encourage the growth of stray cancer cells elsewhere in the body, which may have therapeutic implications. Osteopontin secretion by instigating tumor cells plays a key role in this process.
Researchers at Rutgers University found that beta-endorphin peptide-producing neurons in the brain regulate stress response and immune function, controlling tumor growth. The study shows promise for therapeutic treatments to bolster the immune system.
At 15 mmHg CO2 insufflation pressure, gastric cancer cells' proliferation was inhibited and apoptosis improved. The extracellular pH changed significantly with CO2 versus helium exposure, affecting tumor-cell implantation during laparoscopic surgery.
Researchers found that tumour growth rates vary considerably among patients, with generally slower growth rates with increasing age at diagnosis. The new model estimated the mean time for a tumour to double in size from 10 to 20 mm in diameter is 1.7 years.
Western Australian researchers have made a world-first discovery that could help treat life-threatening tumours by reversing angiogenesis. The team found that the gene RGS5 can normalise blood vessels in tumours, allowing for improved immune cell entry and increased survival rates in laboratory tests.
Scientists have identified 20 new regions of the genome linked to human height, adding to the growing understanding of genetics and growth. These discoveries may shed light on diseases such as osteoarthritis and cancer, and could lead to new avenues for treating various conditions.
A large randomized trial of personalized interventions found that two behavioral interventions did not significantly increase regular mammograms in female veterans. The study's findings support the generalizability to the US female population, which has seen a decline in mammography rates. Meanwhile, another study suggests that viral D...
Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have identified cancer stem cells as a potential cause of brain tumors. The study aims to develop more accurate and specific cancer diagnoses using these stem cells.
A low-carb diet may help stunt prostate tumor growth by reducing insulin production, according to a new study. The study found that mice on a low-carb diet had longer survival and smaller tumors than those on other diets.
Researchers found that PAX5 stimulates the growth of cancerous tumors by spurring cell division normally observed during B cell immune response. This leads to over-expression of key molecules comprising B cell receptor, driving B cell expansion.